Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
Takashi Shigematsu,1 Ryutaro Shimazaki,2 Masafumi Fukagawa,3 Tadao Akizawa4 On behalf of the Evocalcet Study Group 1Department of Nephrology, Wakayama Medical University, Wakayama, Japan; 2R&D Division, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan; 3Department of Internal Medicine, Divi...
Saved in:
Main Authors: | Shigematsu T (Author), Shimazaki R (Author), Fukagawa M (Author), Akizawa T (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans
by: Kazuya Narushima, et al.
Published: (2019) -
THE CARDIOVASCULAR EFFECTS OF CINACALCET IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
by: Sungjin Chung, et al.
Published: (2012) -
Clinical and scanographic mandibular abnormalities in patients with secondary hyperparathyroidism on maintenance hemodialysis
by: Cheboh Cho-Fon, et al.
Published: (2021) -
Parathyroidectomy Reduces Intradialytic Hypotension in Hemodialysis Patients with Secondary Hyperparathyroidism
by: Chia-Jen Shih, et al.
Published: (2013) -
Efficacy and Safety of Etelcalcetide in Hemodialysis Patients with Moderate to Severe Secondary Hyperparathyroidism
by: Paola Monciino, et al.
Published: (2022)